What are the recommended pharmacologic and non‑pharmacologic augmentation strategies for a patient with major depressive disorder who is already taking fluoxetine 60 mg daily?

Augmentation Strategies for Treatment-Resistant Depression on Fluoxetine 60 mg

For a patient with major depressive disorder who has not responded adequately to fluoxetine 60 mg daily, augment with either bupropion or cognitive behavioral therapy (CBT) as the preferred second-step treatment options. Both strategies show similar efficacy with moderate-certainty evidence, though bupropion has lower discontinuation rates due to adverse events compared to buspirone, and CBT offers comparable benefits without the medication-related side effects 1, 2.

Pharmacologic Augmentation Options

First-Line Augmentation Agents

Bupropion is the preferred pharmacologic augmentation agent based on moderate-certainty evidence showing:

• Similar response and remission rates compared to buspirone augmentation
• Significantly lower discontinuation rates due to adverse events (12.5% vs 20.6%, P < 0.001) 2
• Greater reduction in depression severity compared to buspirone 2

Buspirone represents an alternative augmentation option, though with higher adverse event discontinuation rates 2.

Atypical Antipsychotics

For patients requiring more intensive augmentation, atypical antipsychotics show efficacy but come with important tolerability considerations:

• Aripiprazole and quetiapine have the strongest evidence base among atypical antipsychotics 3, 4
• Aripiprazole showed higher remission rates (55.4% vs 34.0%, P = 0.031) compared to bupropion in one trial 1
• Caution: Atypical antipsychotics have higher withdrawal rates due to adverse events and raise concerns about longer-term tolerability and safety 5, 4
• Consider these agents when first-line augmentation strategies have failed

Other Augmentation Agents

Lithium augmentation has established historical efficacy, though the evidence is primarily from studies using tricyclic antidepressants rather than SSRIs 3, 4. The benefit/risk ratio for augmenting modern antidepressants is less clear.

Thyroid hormone (T3/liothyronine) shows efficacy and may offer the best benefit/risk ratio among traditional augmentation strategies, though again, evidence is stronger for TCAs 3, 4.

Non-Pharmacologic Augmentation

Cognitive Behavioral Therapy (CBT) augmentation represents an equally valid option:

• Low-quality evidence shows no difference in response, remission, or depression severity when augmenting with CBT versus bupropion or buspirone 2
• Lower discontinuation rates due to adverse events compared to pharmacologic options (9.2% vs 18.8%, P = 0.086) 1
• May provide longer-term benefits with lower relapse rates compared to medication-only strategies 2
• Should be strongly considered where accessible and based on patient preference 2

Switching Strategies (Alternative Approach)

If augmentation is not preferred, switching to a different second-generation antidepressant is an alternative:

• Moderate-quality evidence shows no significant difference in response rates when switching between SGAs (bupropion, sertraline, or venlafaxine) 2
• Switching to venlafaxine or mirtazapine may potentially offer greater benefits than switching within the SSRI class 3
• Low-quality evidence shows switching to another SGA has similar efficacy to switching to CBT 2

Important caveat: Evidence does not clearly favor switching over augmentation strategies—both approaches show remission rates between 25-50% 3.

Clinical Decision Algorithm

1. First, verify adequate trial: Ensure patient has received fluoxetine 60 mg daily for at least 4-8 weeks 6

2. Choose between augmentation and switching based on:

   • Partial response to fluoxetine → Augmentation preferred
   • No response or intolerable side effects → Consider switching
   • Patient preference and accessibility of CBT

3. If augmenting, select strategy:

   • First choice: Bupropion (better tolerability) or CBT (if accessible, patient preference)
   • Second choice: Buspirone (if bupropion contraindicated)
   • Third choice: Atypical antipsychotics (aripiprazole, quetiapine) for more resistant cases

4. If switching:

   • Consider venlafaxine or mirtazapine over another SSRI
   • Allow adequate washout if needed based on drug interactions

Key Considerations

Adverse event profiles matter: Discuss with patients that:

• Bupropion has lower sexual dysfunction rates than SSRIs 2
• Atypical antipsychotics carry metabolic and movement disorder risks
• CBT has minimal adverse effects but requires time commitment and accessibility

Cost and accessibility: CBT may have limited availability in some settings; pharmacologic augmentation offers more immediate access 2.

Duration of treatment: The evidence base for augmentation strategies extends to 6-12 weeks in most trials 1. Reassess response after adequate trial period.

Common pitfall: Avoid premature switching or augmentation before ensuring an adequate dose and duration trial of the initial antidepressant 6.